Related Experiment Video
Updated: Dec 24, 2025
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma
Chenxing Wu1,2,3, Hongwang Song4, Xiaojun Fu2
1Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Background:
Glioma is the most common and lethal tumor in the central nervous system (CNS). More than 70% of WHO grade II/III gliomas were found to harbor isocitrate dehydrogenase (IDH) mutations which generated targetable metabolic vulnerabilities. Focusing on the metabolic vulnerabilities, some targeted therapies, such as NAMPT, have shown significant effects in preclinical and clinical trials.
Methods:
We explored the TCGA as well as CGGA database and analyzed the RNA-seq data of lower grade gliomas (LGG) with the method of weighted correlation network analysis (WGCNA). Differential expressed genes were screened, and coexpression relationships were grouped together by performing average linkage hierarchical clustering on the topological overlap. Clinical data were used to conduct Kaplan-Meier analysis.
Results:
In this study, we identified ACAA2 as a prognostic factor in IDH mutation lower grade glioma with the method of weighted correlation network analysis (WGCNA). The difference of ACAA2 gene expressions between the IDH wild-type (IDH-WT) group and the IDH mutant (IDH-MUT) group suggested that there may be different potential targeted therapies based on the fatty acid metabolic vulnerabilities, which promoted the personalized treatment for LGG patients.
Insights
ACAA2 is a prognostic factor in isocitrate dehydrogenase (IDH) mutant lower grade gliomas. Its differential expression suggests distinct fatty acid metabolic vulnerabilities, guiding personalized therapies for glioma patients.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Glioma is a lethal central nervous system (CNS) tumor.
- Isocitrate dehydrogenase (IDH) mutations are present in over 70% of WHO grade II/III gliomas.
- IDH mutations create targetable metabolic vulnerabilities, with therapies like NAMPT showing promise.
Purpose of the Study:
- To identify prognostic factors in IDH-mutant lower grade gliomas (LGG).
- To explore potential targeted therapies based on metabolic vulnerabilities.
- To advance personalized treatment strategies for LGG patients.
Main Methods:
- Weighted gene co-expression network analysis (WGCNA) on TCGA and CGGA RNA-seq data.
- Screening of differentially expressed genes and hierarchical clustering.
- Kaplan-Meier analysis using clinical data.
Main Results:
- ACAA2 was identified as a prognostic factor in IDH-mutant LGG.
- Distinct ACAA2 gene expression patterns were observed between IDH-wild-type and IDH-mutant groups.
- These differences suggest potential targeted therapies exploiting fatty acid metabolic vulnerabilities.
Conclusions:
- ACAA2 is a key prognostic marker in IDH-mutant LGG.
- Fatty acid metabolism offers distinct therapeutic avenues for different LGG subtypes.
- Findings support personalized treatment approaches for LGG based on IDH mutation status and metabolic profiles.
More Related Videos
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...